ID   MTOR_HUMAN              Reviewed;        2549 AA.
AC   P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   02-NOV-2010, entry version 111.
DE   RecName: Full=Serine/threonine-protein kinase mTOR;
DE            EC=2.7.11.1;
DE   AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1;
DE   AltName: Full=FKBP12-rapamycin complex-associated protein;
DE   AltName: Full=Mammalian target of rapamycin;
DE            Short=mTOR;
DE   AltName: Full=Mechanistic target of rapamycin;
DE   AltName: Full=Rapamycin target protein 1;
DE            Short=RAPT1;
GN   Name=MTOR; Synonyms=FRAP, FRAP1, FRAP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   MEDLINE=94277209; PubMed=8008069; DOI=10.1038/369756a0;
RA   Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T.,
RA   Lane W.S., Schreiber S.L.;
RT   "A mammalian protein targeted by G1-arresting rapamycin-receptor
RT   complex.";
RL   Nature 369:756-758(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98317532; PubMed=9653645; DOI=10.1006/geno.1997.5186;
RA   Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
RT   "Molecular cloning and expression analysis of five novel genes in
RT   chromosome 1p36.";
RL   Genomics 50:187-198(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549.
RX   MEDLINE=21318995; PubMed=11426320; DOI=10.1038/sj.gene.6363745;
RA   Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C.,
RA   Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S.,
RA   Fujita T., Schwaeble W.;
RT   "The human gene for mannan-binding lectin-associated serine protease-2
RT   (MASP-2), the effector component of the lectin route of complement
RT   activation, is part of a tightly linked gene cluster on chromosome
RT   1p36.2-3.";
RL   Genes Immun. 2:119-127(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY.
RC   TISSUE=B-cell;
RX   MEDLINE=95108000; PubMed=7809080; DOI=10.1073/pnas.91.26.12574;
RA   Chiu M.I., Katz H., Berlin V.;
RT   "RAPT1, a mammalian homolog of yeast Tor, interacts with the
RT   FKBP12/rapamycin complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994).
RN   [8]
RP   SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=9434772; DOI=10.1006/bbrc.1997.7878;
RA   Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M.,
RA   Alarcon C.M., Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.;
RT   "Expression, enzyme activity, and subcellular localization of
RT   mammalian target of rapamycin in insulin-responsive cells.";
RL   Biochem. Biophys. Res. Commun. 241:704-709(1997).
RN   [9]
RP   INTERACTION WITH UBQLN1.
RX   PubMed=11853878; DOI=10.1016/S0167-4889(01)00164-1;
RA   Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.;
RT   "Characterization of ubiquilin 1, an mTOR-interacting protein.";
RL   Biochim. Biophys. Acta 1542:41-56(2002).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH RPTOR.
RX   MEDLINE=22145923; PubMed=12150925; DOI=10.1016/S0092-8674(02)00808-5;
RA   Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "mTOR interacts with raptor to form a nutrient-sensitive complex that
RT   signals to the growth machinery.";
RL   Cell 110:163-175(2002).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH RPTOR.
RX   MEDLINE=22145924; PubMed=12150926; DOI=10.1016/S0092-8674(02)00833-4;
RA   Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S.,
RA   Tokunaga C., Avruch J., Yonezawa K.;
RT   "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR
RT   action.";
RL   Cell 110:177-189(2002).
RN   [12]
RP   INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE TORC1 COMPLEX,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=12408816; DOI=10.1016/S1097-2765(02)00636-6;
RA   Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L.,
RA   Bonenfant D., Oppliger W., Jenoe P., Hall M.N.;
RT   "Two TOR complexes, only one of which is rapamycin sensitive, have
RT   distinct roles in cell growth control.";
RL   Mol. Cell 10:457-468(2002).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11930000; DOI=10.1073/pnas.261702698;
RA   Desai B.N., Myers B.R., Schreiber S.L.;
RT   "FKBP12-rapamycin-associated protein associates with mitochondria and
RT   senses osmotic stress via mitochondrial dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH MLST8.
RX   PubMed=12718876; DOI=10.1016/S1097-2765(03)00114-X;
RA   Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "GbetaL, a positive regulator of the rapamycin-sensitive pathway
RT   required for the nutrient-sensitive interaction between raptor and
RT   mTOR.";
RL   Mol. Cell 11:895-904(2003).
RN   [15]
RP   FUNCTION, IDENTIFICATION IN THE TORC2 COMPLEX, AND INTERACTION WITH
RP   RICTOR.
RX   PubMed=15268862; DOI=10.1016/j.cub.2004.06.054;
RA   Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "Rictor, a novel binding partner of mTOR, defines a rapamycin-
RT   insensitive and raptor-independent pathway that regulates the
RT   cytoskeleton.";
RL   Curr. Biol. 14:1296-1302(2004).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14578359; DOI=10.1074/jbc.M305912200;
RA   Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.;
RT   "FKBP12-rapamycin-associated protein or mammalian target of rapamycin
RT   (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi
RT   apparatus.";
RL   J. Biol. Chem. 279:772-778(2004).
RN   [17]
RP   FUNCTION, IDENTIFICATION IN THE TORC2 COMPLEX, INTERACTION WITH
RP   RICTOR, AND AUTOPHOSPHORYLATION.
RX   PubMed=15467718; DOI=10.1038/ncb1183;
RA   Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A.,
RA   Hall M.N.;
RT   "Mammalian TOR complex 2 controls the actin cytoskeleton and is
RT   rapamycin insensitive.";
RL   Nat. Cell Biol. 6:1122-1128(2004).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1.
RX   PubMed=15718470; DOI=10.1126/science.1106148;
RA   Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.;
RT   "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
RT   complex.";
RL   Science 307:1098-1101(2005).
RN   [19]
RP   IDENTIFICATION IN THE TORC2 COMPLEX, AND INTERACTION WITH PRR5.
RX   PubMed=17599906; DOI=10.1074/jbc.M704343200;
RA   Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I.,
RA   Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.;
RT   "PRR5, a novel component of mTOR complex 2, regulates platelet-derived
RT   growth factor receptor beta expression and signaling.";
RL   J. Biol. Chem. 282:25604-25612(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1162, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [21]
RP   IDENTIFICATION IN THE TORC1 AND TORC2 COMPLEXES, AND FUNCTION IN
RP   PHOSPHORYLATION OF S6K AND SGK1.
RX   PubMed=18925875; DOI=10.1042/BJ20081668;
RA   Garcia-Martinez J.M., Alessi D.R.;
RT   "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation
RT   and activation of serum- and glucocorticoid-induced protein kinase 1
RT   (SGK1).";
RL   Biochem. J. 416:375-385(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND SER-1261, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18497260; DOI=10.1126/science.1157535;
RA   Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C.,
RA   Bar-Peled L., Sabatini D.M.;
RT   "The Rag GTPases bind raptor and mediate amino acid signaling to
RT   mTORC1.";
RL   Science 320:1496-1501(2008).
RN   [25]
RP   INTERACTION WITH DEPDC6.
RX   PubMed=19446321; DOI=10.1016/j.cell.2009.03.046;
RA   Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A.,
RA   Kuehl W.M., Gray N.S., Sabatini D.M.;
RT   "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple
RT   myeloma cells and required for their survival.";
RL   Cell 137:873-886(2009).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567; SER-916; SER-1261;
RP   THR-1829; THR-1839; THR-1840; THR-1841; SER-1843; SER-1847; SER-1849;
RP   SER-1851; THR-1856; SER-1859; SER-1863; SER-2448; TYR-2449 AND
RP   THR-2471, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND MASS SPECTROMETRY.
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [29]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112.
RX   MEDLINE=96279639; PubMed=8662507; DOI=10.1126/science.273.5272.239;
RA   Choi J., Chen J., Schreiber S.L., Clardy J.;
RT   "Structure of the FKBP12-rapamycin complex interacting with the
RT   binding domain of human FRAP.";
RL   Science 273:239-242(1996).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112.
RX   MEDLINE=99190960; PubMed=10089303; DOI=10.1107/S0907444998014747;
RA   Liang J., Choi J., Clardy J.;
RT   "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2
RT   A resolution.";
RL   Acta Crystallogr. D 55:736-744(1999).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134;
RP   PHE-1178; VAL-2011; TYR-2215 AND LEU-2476.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Kinase subunit of both mTORC1 and mTORC2, which regulate
CC       cell growth and survival in response to nutrient and hormonal
CC       signals. mTORC1 is activated in response to growth factors or
CC       amino-acids. Amino-acid-signaling to mTORC1 is mediated by Rag
CC       GTPases, which cause amino-acid-induced relocalization of mTOR
CC       within the endomembrane system. Growth factor-stimulated mTORC1
CC       activation involves AKT1-mediated phosphorylation of TSC1-TSC2,
CC       which leads to the activation of the RHEB GTPase that potently
CC       activates the protein kinase activity of mTORC1. Activated mTORC1
CC       up-regulates protein synthesis by phosphorylating key regulators
CC       of mRNA translation and ribosome synthesis. mTORC1 phosphorylates
CC       EIF4EBP1 and releases it from inhibiting the elongation initiation
CC       factor 4E (eiF4E). mTORC1 phosphorylates and activates S6K1 at
CC       'Thr-421', which then promotes protein synthesis by
CC       phosphorylating PDCD4 and targeting it for degradation. mTORC2 is
CC       also activated by growth factors, but seems to be nutrient-
CC       insensitive. mTORC2 seems to function upstream of Rho GTPases to
CC       regulate the actin cytoskeleton, probably by activating one or
CC       more Rho-type guanine nucleotide exchange factors. mTORC2 promotes
CC       the serum-induced formation of stress-fibers or F-actin. mTORC2
CC       plays a critical role in AKT1 'Ser-473' phosphorylation, which may
CC       facilitate the phosphorylation of the activation loop of AKT1 on
CC       'Thr-308' by PDK1 which is a prerequisite for full activation.
CC       mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2
CC       also modulates the phosphorylation of PRKCA on 'Ser-657'.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Kinase activity is positively regulated by RHEB
CC       and negatively regulated by DEPDC6.
CC   -!- SUBUNIT: Interacts with PPAPDC3 (By similarity). Part of the
CC       mammalian target of rapamycin complex 1 (mTORC1) which contains
CC       MTOR/FRAP1, MLST8, RPTOR and AKT1S1. mTORC1 binds to and is
CC       inhibited by FKBP12-rapamycin. Part of the mammalian target of
CC       rapamycin complex 2 (mTORC2) which contains FRAP1, MLST8, PROTOR1,
CC       RICTOR and MAPKAP1. Contrary to mTORC1, mTORC2 does not bind to
CC       and is not sensitive to FKBP12-rapamycin. Binds directly to
CC       PROTOR1 and RICTOR within the mTORC2 complex. Interacts with
CC       UBQLN1. Interacts with DEPDC6. Interacts with TTI1 and TELO2.
CC   -!- INTERACTION:
CC       Q8TB45:DEPDC6; NbExp=2; IntAct=EBI-359260, EBI-2359040;
CC       Q13541:EIF4EBP1; NbExp=1; IntAct=EBI-359260, EBI-74090;
CC       P62942:FKBP1A; NbExp=1; IntAct=EBI-359260, EBI-1027571;
CC       Q9BVC4:MLST8; NbExp=1; IntAct=EBI-359260, EBI-1387471;
CC       Q8TCU6:PREX1; NbExp=7; IntAct=EBI-359260, EBI-1046542;
CC       Q70Z35:PREX2; NbExp=2; IntAct=EBI-359260, EBI-1790593;
CC       Q6R327:RICTOR; NbExp=1; IntAct=EBI-359260, EBI-1387196;
CC       Q8N122:RPTOR; NbExp=3; IntAct=EBI-359260, EBI-1567928;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein; Cytoplasmic side. Golgi apparatus membrane;
CC       Peripheral membrane protein; Cytoplasmic side. Mitochondrion outer
CC       membrane; Peripheral membrane protein; Cytoplasmic side.
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest
CC       levels in testis.
CC   -!- PTM: Autophosphorylated; when part of mTORC1 or mTORC2.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC   -!- SIMILARITY: Contains 1 FAT domain.
CC   -!- SIMILARITY: Contains 1 FATC domain.
CC   -!- SIMILARITY: Contains 7 HEAT repeats.
CC   -!- SIMILARITY: Contains 1 PI3K/PI4K domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39933.1; Type=Frameshift; Positions=956, 999;
CC       Sequence=BAE06077.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FRAP1ID40639ch1p36.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin
CC       entry;
CC       URL="http://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin";
CC   -!- WEB RESOURCE: Name=Target mTOR; Note=mTOR signaling pathway and
CC       mTOR inhibition resource;
CC       URL="http://www.targetmtor.com/index.jsp";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L34075; AAA58486.1; -; mRNA.
DR   EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA.
DR   EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA.
DR   EMBL; AL109811; CAI22105.1; -; Genomic_DNA.
DR   EMBL; AL049653; CAI22105.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI22105.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI17228.1; -; Genomic_DNA.
DR   EMBL; AL049653; CAI17228.1; JOINED; Genomic_DNA.
DR   EMBL; AL109811; CAI17228.1; JOINED; Genomic_DNA.
DR   EMBL; AL049653; CAI22145.1; -; Genomic_DNA.
DR   EMBL; AL109811; CAI22145.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI22145.1; JOINED; Genomic_DNA.
DR   EMBL; BC117166; AAI17167.1; -; mRNA.
DR   EMBL; AJ300188; CAC15570.1; -; Genomic_DNA.
DR   EMBL; L35478; AAC41713.1; -; mRNA.
DR   IPI; IPI00031410; -.
DR   PIR; S45340; S45340.
DR   RefSeq; NP_004949.1; -.
DR   UniGene; Hs.338207; -.
DR   PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114.
DR   PDB; 1FAP; X-ray; 2.70 A; B=2018-2112.
DR   PDB; 1NSG; X-ray; 2.20 A; B=2019-2112.
DR   PDB; 2FAP; X-ray; 2.20 A; B=2019-2112.
DR   PDB; 2GAQ; NMR; -; A=2015-2114.
DR   PDB; 2NPU; NMR; -; A=2015-2114.
DR   PDB; 3FAP; X-ray; 1.85 A; B=2019-2112.
DR   PDB; 4FAP; X-ray; 2.80 A; B=2019-2112.
DR   PDBsum; 1AUE; -.
DR   PDBsum; 1FAP; -.
DR   PDBsum; 1NSG; -.
DR   PDBsum; 2FAP; -.
DR   PDBsum; 2GAQ; -.
DR   PDBsum; 2NPU; -.
DR   PDBsum; 3FAP; -.
DR   PDBsum; 4FAP; -.
DR   ProteinModelPortal; P42345; -.
DR   SMR; P42345; 22-213, 187-215, 2517-2549.
DR   DIP; DIP-790N; -.
DR   IntAct; P42345; 80.
DR   MINT; MINT-121301; -.
DR   STRING; P42345; -.
DR   PhosphoSite; P42345; -.
DR   PRIDE; P42345; -.
DR   Ensembl; ENST00000361445; ENSP00000354558; ENSG00000198793.
DR   GeneID; 2475; -.
DR   KEGG; hsa:2475; -.
DR   UCSC; uc001asd.1; human.
DR   CTD; 2475; -.
DR   GeneCards; GC01M011166; -.
DR   HGNC; HGNC:3942; MTOR.
DR   HPA; CAB005057; -.
DR   MIM; 601231; gene.
DR   PharmGKB; PA28360; -.
DR   eggNOG; prNOG04608; -.
DR   HOVERGEN; HBG005744; -.
DR   InParanoid; P42345; -.
DR   OMA; DKYCKDL; -.
DR   OrthoDB; EOG9BP3XD; -.
DR   PhylomeDB; P42345; -.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; il12_2pathway; IL12-mediated signaling events.
DR   Pathway_Interaction_DB; il2_pi3kpathway; IL2 signaling events mediated by PI3K.
DR   Pathway_Interaction_DB; il4_2pathway; IL4-mediated signaling events.
DR   Pathway_Interaction_DB; mtor_4pathway; mTOR signaling pathway.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   NextBio; 9805; -.
DR   ArrayExpress; P42345; -.
DR   Bgee; P42345; -.
DR   CleanEx; HS_FRAP1; -.
DR   Genevestigator; P42345; -.
DR   GermOnline; ENSG00000198793; Homo sapiens.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005942; C:phosphoinositide 3-kinase complex; NAS:UniProtKB.
DR   GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB.
DR   GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0016049; P:cell growth; TAS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:MGI.
DR   GO; GO:0030163; P:protein catabolic process; TAS:UniProtKB.
DR   GO; GO:0043200; P:response to amino acid stimulus; IDA:UniProtKB.
DR   GO; GO:0007584; P:response to nutrient; NAS:UniProtKB.
DR   GO; GO:0031929; P:TOR signaling cascade; IMP:UniProtKB.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC.
DR   InterPro; IPR009076; FKBP_rapamycin-assoc_FKBP12-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   Gene3D; G3DSA:1.25.10.10; ARM-like; 3.
DR   Gene3D; G3DSA:1.20.120.150; FRAP_FKBP12_bd; 1.
DR   Gene3D; G3DSA:1.10.1070.11; PI3/4_kinase_cat; 3.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF08771; Rapamycin_bind; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM-type_fold; 2.
DR   SUPFAM; SSF47212; FRAP_FKBP12_bind; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS50077; HEAT_REPEAT; FALSE_NEG.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome;
KW   Endoplasmic reticulum; Golgi apparatus; Kinase; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Repeat; Transferase.
FT   CHAIN         1   2549       Serine/threonine-protein kinase mTOR.
FT                                /FTId=PRO_0000088808.
FT   REPEAT       16     53       HEAT 1.
FT   REPEAT      650    688       HEAT 2.
FT   REPEAT      859    897       HEAT 3.
FT   REPEAT      988   1025       HEAT 4.
FT   REPEAT     1069   1106       HEAT 5.
FT   REPEAT     1109   1148       HEAT 6.
FT   REPEAT     1150   1186       HEAT 7.
FT   DOMAIN     1382   1982       FAT.
FT   DOMAIN     2182   2516       PI3K/PI4K.
FT   DOMAIN     2517   2549       FATC.
FT   MOD_RES     567    567       Phosphoserine.
FT   MOD_RES     916    916       Phosphoserine.
FT   MOD_RES    1162   1162       Phosphothreonine.
FT   MOD_RES    1218   1218       N6-acetyllysine.
FT   MOD_RES    1261   1261       Phosphoserine.
FT   MOD_RES    1829   1829       Phosphothreonine.
FT   MOD_RES    1839   1839       Phosphothreonine.
FT   MOD_RES    1840   1840       Phosphothreonine.
FT   MOD_RES    1841   1841       Phosphothreonine.
FT   MOD_RES    1843   1843       Phosphoserine.
FT   MOD_RES    1847   1847       Phosphoserine.
FT   MOD_RES    1849   1849       Phosphoserine.
FT   MOD_RES    1851   1851       Phosphoserine.
FT   MOD_RES    1856   1856       Phosphothreonine.
FT   MOD_RES    1859   1859       Phosphoserine.
FT   MOD_RES    1863   1863       Phosphoserine.
FT   MOD_RES    2448   2448       Phosphoserine.
FT   MOD_RES    2449   2449       Phosphotyrosine.
FT   MOD_RES    2471   2471       Phosphothreonine.
FT   MOD_RES    2478   2478       Phosphoserine.
FT   MOD_RES    2481   2481       Phosphoserine.
FT   VARIANT       8      8       A -> S (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041537.
FT   VARIANT     135    135       M -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041538.
FT   VARIANT    1083   1083       M -> V (in dbSNP:rs56164650).
FT                                /FTId=VAR_041539.
FT   VARIANT    1134   1134       A -> V (in dbSNP:rs28730685).
FT                                /FTId=VAR_041540.
FT   VARIANT    1178   1178       S -> F (in dbSNP:rs55975118).
FT                                /FTId=VAR_041541.
FT   VARIANT    2011   2011       M -> V (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041542.
FT   VARIANT    2215   2215       S -> Y (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041543.
FT   VARIANT    2476   2476       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041544.
FT   CONFLICT    353    353       K -> N (in Ref. 2; AAC39933).
FT   CONFLICT    359    359       S -> N (in Ref. 2; AAC39933).
FT   CONFLICT    364    364       D -> N (in Ref. 2; AAC39933).
FT   CONFLICT    390    390       M -> L (in Ref. 2; AAC39933).
FT   CONFLICT    430    430       R -> L (in Ref. 2; AAC39933).
FT   CONFLICT    455    457       VLD -> GVE (in Ref. 2; AAC39933).
FT   CONFLICT    461    461       A -> G (in Ref. 2; AAC39933).
FT   CONFLICT    482    484       VFT -> FFN (in Ref. 2; AAC39933).
FT   CONFLICT    489    489       L -> V (in Ref. 2; AAC39933).
FT   CONFLICT    513    513       L -> I (in Ref. 2; AAC39933).
FT   CONFLICT    539    539       L -> V (in Ref. 2; AAC39933).
FT   CONFLICT    553    553       R -> C (in Ref. 2; AAC39933).
FT   CONFLICT    857    857       P -> L (in Ref. 3; BAE06077).
FT   CONFLICT   1075   1075       I -> S (in Ref. 2; AAC39933).
FT   HELIX      2023   2039
FT   HELIX      2044   2059
FT   HELIX      2065   2091
FT   HELIX      2095   2110
SQ   SEQUENCE   2549 AA;  288892 MW;  7D9AD6E784882AB4 CRC64;
     MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES
     TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP
     VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP
     TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE
     AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC
     KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR
     CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV
     LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA
     TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL
     KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT
     QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL
     VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS
     MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI
     LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA
     LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK
     VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR
     DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV
     SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR
     VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD
     RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV
     RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV
     STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA
     AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI
     VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF
     GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK
     WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA
     QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW
     ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD
     PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK
     QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA
     VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP
     TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN
     EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS
     KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG
     ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA
     WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL
     QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL
     SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL
     MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH
     PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC
     HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG
     VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD
     VPTQVELLIK QATSHENLCQ CYIGWCPFW
//
